KING OF PRUSSIA, Pa., Feb. 11, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted Privigen® (Immune Globulin ...
KING OF PRUSSIA, Pa., Feb. 21, 2013 /PRNewswire/ -- CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen®, immune ...
Privigen (human immunoglobulin G) is a prescription drug used to treat certain immune system conditions. The drug comes as an intravenous (IV) infusion (an injection into a vein given over time).
CSL Behring announced that the FDA has approved a 40g (400mL) vial size for Privigen (immune globulin intravenous [human] 0.1g/mL). The new vial size will reduce the required number of individual vial ...
This pilot open label study investigated the safety and preliminary efficacy of using IVIG over a 6-month period for treatment of MSA. IVIG treatment was well tolerated. Post-treatment functional ...
Data published online in the current edition of Journal of Clinical Immunology demonstrates that Privigen TM, the new liquid immune globulin intravenous (human) 10 percent product from CSL Behring, is ...
Privigen (human immunoglobulin g) can cause side effects that range from mild to serious. More common side effects include headache and nausea. If side effects from Privigen become difficult to ...
The FDA approval was based on data from two Phase 3 studies, PATH and PRIMA. CSL Behring announced that the Food and Drug Administration (FDA) has approved Privigen (immune globulin intravenous [human ...
This was a single-arm, interventional-, single-center, open-label prospective study. Patients with a history of probable MSA [15] were enrolled in the study (Table 1). All patients had some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results